CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Addex Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Addex Therapeutics Ltd
Chemin des Aulx 12, Case Postale 68
Phone: +41 228841555p:+41 228841555 PLAN-LES-OUATES, 1228  Switzerland Ticker: ADXNADXN

Business Summary
Addex Therapeutics Ltd is a Switzerland-based company, that discovers and develops a class of small molecule drugs, allosteric modulators. Its two products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or is being developed by the Company to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by its partner Janssen Pharmaceuticals Inc. to treat schizophrenia. It also is advancing several preclinical programs, including GABA-BR PAM for pain, overactive bladder and other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression, and FSHR/LHR NAM for sex hormone dependent tumors and reproductive system disorders. In addition, it has discovery programs to identify allosteric modulators of receptor tyrosine kinase superfamily
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201912/31/2018Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board of Directors VincentLawton 70 1/1/2016 4/17/2009
Chief Executive Officer, Member of the Executive Board, Member of the Board of Directors TimDyer 50 1/1/2015 1/1/2015
Member of the Executive Board, Chief Medical Officer, Member of the Board of Directors Roger G.Mills 61 1/1/2017 11/28/2016
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Addex Pharma SA
Addex Pharmaceuticals
Addex Pharmaceuticals France SAS
4 additional Business Names available in full report.

General Information
Number of Employees: 17 (As of 12/31/2018)
Outstanding Shares: 26,485,119 (As of 6/30/2019)
Shareholders: 2,346
Stock Exchange: SWF
Fax Number: +41 228841556


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 08, 2019